e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Lung cancer: prognostic factors and features of oncogene-driven tumours
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Shivalingaswamy Salimath (Davangere, India), Shivalingaswamy Salimath, B.S. Jayaraj, P.A. Mahesh
Source:
International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Session:
Lung cancer: prognostic factors and features of oncogene-driven tumours
Session type:
Thematic Poster Session
Number:
4255
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Shivalingaswamy Salimath (Davangere, India), Shivalingaswamy Salimath, B.S. Jayaraj, P.A. Mahesh. Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival. Eur Respir J 2015; 46: Suppl. 59, 4255
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin
Source: Annual Congress 2013 –Basic research on lung cancer
Year: 2013
Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018
Lung cancer patients harbouring epidermal growth factor receptor mutation
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC)
Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series
Year: 2014
The diagnosis and incidence of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutation in lung adenocarcinoma
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010
The influence of erythropoietin on growth and survival in non-small cell lung cancer cell lines
Source: International Congress 2015 – Cell biology of lung cancer and new biomarkers
Year: 2015
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Source: Eur Respir J 2005; 25: 329-335
Year: 2005
Clinical significance of erythropoietin (Epo) and its receptor (EpoR) in non-small cell lung carcinoma
Source: International Congress 2014 – Biology and pathology of thoracic tumours
Year: 2014
Risk factor for survival in never-smokers non-small cell lung cancer (NSCLC)
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010
beta-F1-ATPase expression as a prognostic factor for resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Prognostic impact of secondary malignancies in non-small cell lung cancer (NSCLC)
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience
Source: Annual Congress 2012 - New biomarkers for lung cancer
Year: 2012
A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas
Source: International Congress 2016 – Molecular targets in pulmonary disease
Year: 2016
Unexpected hair growth induced by gefitinib treatment in two patients with EGFR gene mutation-positive adenocarcinoma of the lung
Source: International Congress 2015 – Diagnosis and therapy of lung cancer
Year: 2015
Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
Source: Eur Respir J 2011; 38: 903-910
Year: 2011
Predicting activity of EGFR (epidermal growth factor receptor) inhibitors in diffuse bronchiolo-alveolar carcinoma or so-called pneumonic adenocarcinoma
Source: Annual Congress 2006 - Bronchiolo-alveolar carcinoma
Year: 2006
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept